Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680427 · ClinicalTrials.gov registry record · NA
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
A NA study of Aortic Stenosis Symptomatic, sponsored by MiRus.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT06680427: Active NA study of Aortic Stenosis Symptomatic, sponsored by MiRus.
NCT06680427 is a NA study of Aortic Stenosis Symptomatic that is active but no longer recruiting, run by MiRus. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06680427, a NA study of Aortic Stenosis Symptomatic, is active but no longer recruiting, sponsored by MiRus.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
Primary Outcome
Technical success will be reported as freedom from mortality, successful device implant, and freedom from surgery or intervention related to the device.
Conditions Studied
Interventions
- DEVICE Siegel Transcatheter Aortic Valve (TAVR)
Study Locations (8)
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford - Palo Alto
Florida
- NCH Healthcare System - Naples
Georgia
- Piedmont Healthcare - Atlanta
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Atlantic Health System - Morristown
New York
- Columbia University Medical Center/ NYPH - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT06680427 still lists
NCT06680427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Aortic Stenosis Symptomatic appearing as the primary indexed condition, and to 1 intervention - of which Siegel Transcatheter Aortic Valve (TAVR) is the first listed.
NCT06680427 lists 8 locations in 7 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT06680427 about?
NCT06680427 is a clinical study titled "Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study". The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
What is the current status of trial NCT06680427?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-26. Estimated completion is 2025-12.
What conditions does trial NCT06680427 study?
This clinical trial studies the following conditions: Aortic Stenosis Symptomatic.
What interventions are being tested in trial NCT06680427?
The interventions under investigation include: Siegel Transcatheter Aortic Valve (TAVR) (DEVICE).
Who is sponsoring clinical trial NCT06680427?
This trial is sponsored by MiRus, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06680427 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06680427's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI